SynthesisInternational urogynecology journal and pelvic floor dysfunction2008
Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences.
Synthesis in International urogynecology journal and pelvic floor dysfunction, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 27 citations in OpenAlex.
- Male Urinary Incontinence Severity and Non-Adjustable Sling Outcomes: Protocol for a Multivariate Dose-Response Meta-Analysis.Journal of clinical medicine · 2026Review
- Pharmacological Management of Urinary Incontinence: Current and Emerging Treatment.Clinical pharmacology : advances and applications · 2021Review
- KNaunyn-Schmiedeberg's archives of pharmacology · 2017Article
- Pharmacological methods for the preclinical assessment of therapeutics for OAB: an up-to-date review.International urogynecology journal · 2016Review
- Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?International urogynecology journal · 2015Review
- Mirabegron: a review of recent data and its prospects in the management of overactive bladder.Therapeutic advances in urology · 2012Article
- Social, economic, and health utility considerations in the treatment of overactive bladder.Open access journal of urology · 2010Review
- Triple therapy in refractory detrusor overactivity: a preliminary study.World journal of urology · 2010Article
- Prospective pharmacologic therapies for the overactive bladder.Therapeutic advances in urology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimuscarinics are the mainstay of the medical therapy for overactive bladder, but their side effects and often modest success have prompted studies on novel pharmacological approaches. In this paper, we give a systematic literature review of peer-reviewed papers on the subject. Effective nonantimuscarinic treatments are currently scarce, but many new promising compounds are emerging, which target key molecular pathways involved in micturition control. The most promising potential therapeutic targets include: nervous GABAergic, glycinergic, dopaminergic, and serotonergic systems; b-adrenoceptors and cAMP metabolism; nonadrenergic-noncholinergic mechanisms such as purinergic and neuropeptidergic systems; vanilloid receptors; bladder afferent nerves; nonneuronal bladder signaling systems including urothelium and interstitial cells; prostanoids; Rho-kinase; and different subtypes of potassium and calcium channels. Despite the enormous amount of new biologic insight, very few drugs with mechanism of action other than antimuscarinics have passed as yet the proof-of-concept stage. Further preclinical and clinical studies are urgently needed in this rapidly moving field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.